Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesKevin R. Flaherty, Kevin K. Brown, Athol U. Wells et al.|New England Journal of Medicine|2019Cited by 2.3k
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care JournalsDavid J. Lederer, Jean‐Louis Vincent, Scott C. Bell et al.|Annals of the American Thoracic Society|2018Cited by 723
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trialAthol U. Wells, Daniel F. Dilling, Luca Richeldi et al.|The Lancet Respiratory Medicine|2020Cited by 558
What's in a name? That which we call IPF, by any other name would act the sameAthol U. Wells, Victor J. Thannickal, Kevin K. Brown et al.|European Respiratory Journal|2018Cited by 352
VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in ratsLászló Farkas, Martin Kolb|Journal of Clinical Investigation|2009Cited by 221